Detalhe da pesquisa
1.
A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey.
Br J Dermatol
; 179(1): 173-181, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29328510
2.
Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
Br J Dermatol
; 178(6): 1297-1307, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29355896
3.
Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
J Eur Acad Dermatol Venereol
; 32(12): 2178-2184, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29846965
4.
Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
J Eur Acad Dermatol Venereol
; 32(12): 2191-2199, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29729105
5.
Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey.
J Eur Acad Dermatol Venereol
; 32(9): 1523-1529, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29524271
6.
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Br J Dermatol
; 177(4): 1033-1042, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28580579
7.
Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries.
J Eur Acad Dermatol Venereol
; 31(8): 1316-1323, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28426138
8.
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
J Eur Acad Dermatol Venereol
; 31(10): 1693-1699, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28602039
9.
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Ann Oncol
; 27(10): 1940-6, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27405322